Deals in Depth: April 2008
April 2008 dealmaking highlights include: Astellas Pharma penned a $760mm alliance with CoMentis for a novel Alzheimer's disease target; Novartis and Takeda each made billion-dollar acquisitions: Novartis continues to diversify its offerings through the Alcon buy, and Takeda is extending its overseas presence and adding to its cancer pipeline in the Millennium deal. Public investors were absent from biopharma financing, while 25% of medical device investments came from follow-ons.
You may also be interested in...
Although oncology remained strong, Japanese major says it saw multiple impacts from the pandemic, including on hospital visits and clinical trial recruitment, and has already cut its full-year guidance.
AdvaMed’s VentConnect platform is expanding to support production of devices needed to treat COVID-19. Here’s what Eric Fanning, CEO of participating group the Aerospace Industries Association, said about the move.
Preliminary plans for an Oct. 22 meeting of US FDA's vaccine advisory committee suggest a fast evaluation of COVID-19 immunizations, bringing mixed reactions from onlookers who say it could be a positive sign of needed public transparency or an indication the agency is rushing to approve a product ahead of the November presidential election.